Nctid:
NCT06232161
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-12-20"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D009216", "term"=>"Myopia"}], "ancestors"=>[{"id"=>"D012030", "term"=>"Refractive Errors"}, {"id"=>"D005128", "term"=>"Eye Diseases"}], "browseLeaves"=>[{"id"=>"M12168", "name"=>"Myopia", "asFound"=>"Myopia", "relevance"=>"HIGH"}, {"id"=>"M14872", "name"=>"Refractive Errors", "relevance"=>"LOW"}, {"id"=>"M8271", "name"=>"Eye Diseases", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Eye Diseases", "abbrev"=>"BC11"}, {"name"=>"All Conditions", "abbrev"=>"All"}]}, "interventionBrowseModule"=>{"browseLeaves"=>[{"id"=>"M16759", "name"=>"Tin Fluorides", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["NA"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"NON_RANDOMIZED", "maskingInfo"=>{"masking"=>"NONE"}, "primaryPurpose"=>"TREATMENT", "interventionModel"=>"PARALLEL", "interventionModelDescription"=>"The first 12-month follow-up were parallel of two groups: treatment group and control group with randomized and single blind; While the second 12-month follow-up were chosen to be in the treatment group or in the control group depended on the willingness of red-light therapy from both patients and their family."}, "enrollmentInfo"=>{"type"=>"ACTUAL", "count"=>50}}, "statusModule"=>{"overallStatus"=>"ACTIVE_NOT_RECRUITING", "startDateStruct"=>{"date"=>"2020-05-13", "type"=>"ACTUAL"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2024-02", "completionDateStruct"=>{"date"=>"2026-12-31", "type"=>"ESTIMATED"}, "lastUpdateSubmitDate"=>"2024-02-12", "studyFirstSubmitDate"=>"2024-01-20", "studyFirstSubmitQcDate"=>"2024-01-20", "lastUpdatePostDateStruct"=>{"date"=>"2024-02-14", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"2024-01-30", "type"=>"ACTUAL"}, "primaryCompletionDateStruct"=>{"date"=>"2024-12-31", "type"=>"ESTIMATED"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"Change of axial length (mm) with the measurement of device named by IntraOcular Lens Master(IOLmaster 500)", "timeFrame"=>"12-month", "description"=>"The change of axial length (mm) from the 24 months and 12 months from the baseline for each subject; The right eye were considered for the comparison between groups.\n\nThe change value is recorded of the average from 5 values at the same follow-up"}], "secondaryOutcomes"=>[{"measure"=>"Change of refractive error (D) with cycloplegic refraction with the same autorefractor", "timeFrame"=>"12-month", "description"=>"The change of refractive error (D) from the follow-up of each 12-month from the baseline. The right eye were considered for the comparison"}]}, "oversightModule"=>{"oversightHasDmc"=>false, "isFdaRegulatedDrug"=>false, "isFdaRegulatedDevice"=>false}, "conditionsModule"=>{"keywords"=>["myopia, red-light therapy"], "conditions"=>["Myopia"]}, "referencesModule"=>{"references"=>[{"pmid"=>"36849626", "type"=>"RESULT", "citation"=>"Zhou L, Tong L, Li Y, Williams BT, Qiu K. Photobiomodulation therapy retarded axial length growth in children with myopia: evidence from a 12-month randomized controlled trial evidence. Sci Rep. 2023 Feb 27;13(1):3321. doi: 10.1038/s41598-023-30500-7."}], "seeAlsoLinks"=>[{"url"=>"https://pubmed.ncbi.nlm.nih.gov/36849626/", "label"=>"The first 12-month follow-up report of PBM therapy"}]}, "descriptionModule"=>{"briefSummary"=>"To evaluate the long-term efficacy and safety of red-light therapy for myopia control over 2 years, and the potential rebound effect after treatment cessation.\n\nThe Chinese myopic children who originally completed the one-year randomised controlled trial in the previous study were enrolled. Children continued or started to daily usage of red-light therapy were defined as the RL group, while those who stopped using red-light therapy and switched to single-vision spectacles (SVS) as well as those who continued to keep single-vision spectacles in the second year were both regarded as the SVS group. Red-light therapy was provided by an at-home desktop light device emitting red-light of 650 nm and was administered for 3 min at a time, twice a day. Changes in axial length (AL) and cycloplegic spherical equivalence refraction (SER) are to be measured and compared as well as the adverse effects including the rebound effect.\n\nRed-light therapy has emerged as a novel myopia control treatment modality recently. A 12-month randomised controlled trial (RCT) conducted by our research team was thought to be earlier to evaluate the treatment of myopic children using red-light therapy. The trial demonstrated that PBM therapy was effective on myopia control, reducing axial elongation and spherical equivalence refraction (SER) progression 103% and 127% compared with single vision spectacle (SVS) over a 12-month period, respectively. The promising efficacy of red-light therapy has been further confirmed in other studies. In addition, satisfactory user acceptability and no unrecovered functional and structural damages were observed.\n\nMyopia generally progresses throughout childhood and hence a study duration of 1 year is not sufficient to widely adopt the red-light therapy as a treatment strategy for myopia control. The sustainability of treatment efficacy, rebound phenomenon upon cessation of treatment, and potential risks and adverse effects in myopic children with longer-term PBM therapy, remain to be fully elucidated.\n\nThus, the aims of this post-trial follow-up study were to invite the participants to come back for a 24-month visit and to investigate the long-term efficacy and safety of continued red-light therapy as well as the potential rebound effect following red-light treatment cessation.", "detailedDescription"=>"Interventions and visits All spectacle lenses were made for single focus with full correction for each subject as the first intervention throughout the whole procedure for both groups. PBM therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average at the first 12 month. At the second 12 months, non-randomized cohorts continued according to the willing to use the device from both groups. Once decided, those usage would be followed up for another 12 months for tracking the change of axial length as well as the change of refractive error. All the adverse effects and any harms are encouraged to report during the next 12 months' study."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["CHILD"], "maximumAge"=>"13 years", "minimumAge"=>"9 years", "healthyVolunteers"=>true, "eligibilityCriteria"=>"Inclusion Criteria:\n\n1. Clinical diagnosis of myopia;\n2. Ages of 9\\~13 years old;\n3. Must be with best corrected visual acuity ≥20/25 (decimal record);\n4. Must be the subject in the previous study of 12-month red-light therapy of myopia;\n\nExclusion Criteria:\n\n1. Clinical diagnosis of glaucoma or retinal lesions;\n2. Clinical diagnosis of optic media lesions (e.g., central thick corneal scars, cataract);\n3. Clinical diagnosis of optic nerve dysfunction;\n4. Clinical diagnosis of amblyopia;\n5. Must be eligible for follow-up."}, "identificationModule"=>{"nctId"=>"NCT06232161", "briefTitle"=>"Sustained Effect of Red-light Therapy for Myopia Control: A 2-Year Post-Trial Follow-up Study", "organization"=>{"class"=>"INDUSTRY", "fullName"=>"Beijing Airdoc Technology Co., Ltd."}, "officialTitle"=>"Retrospective,2-Year Post-Trial Follow-up Study of Sustained and Rebound Effect of Red-light Therapy for Myopia in Ningbo.", "orgStudyIdInfo"=>{"id"=>"Ningbo EYE Hospital"}}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"EXPERIMENTAL", "label"=>"red-light therapy group", "description"=>"The red-light therapy group would be treated with red-light therapy twice daily including the single focus spectacles during the follow-up.", "interventionNames"=>["Device: Red-light therapy device", "Device: Spectacles"]}, {"type"=>"OTHER", "label"=>"control group", "description"=>"The control group including both the stopping red-light therapy group from the first 12 months (who obtained red-light therapy but stopped during the second 12-month follow-up) and those never use red-light therapy.", "interventionNames"=>["Device: Spectacles"]}], "interventions"=>[{"name"=>"Red-light therapy device", "type"=>"DEVICE", "otherNames"=>["Repeated low-level red-light (RLRL) therapy", "Low intensity red light (laser) therapy", "Photobiomodulation therapy (PBM) therapy"], "description"=>"Red-light therapy was performed with a low-intensity laser (LD-A, Jilin LD Optoelectronics Technology, Jilin, China) with an irradiance of 0.35 ± 0.02 mW/cm2, a wavelength of 650 nm ± 10 nm, and illumination of approximately 400 lux on average.", "armGroupLabels"=>["red-light therapy group"]}, {"name"=>"Spectacles", "type"=>"DEVICE", "description"=>"Single focus spectacles, that is to say, wearing glasseses with minus power lens", "armGroupLabels"=>["control group", "red-light therapy group"]}]}, "contactsLocationsModule"=>{"locations"=>[{"zip"=>"315000", "city"=>"Ningbo", "state"=>"Zhejiang", "country"=>"China", "facility"=>"Ningbo Eye Hospital", "geoPoint"=>{"lat"=>29.87819, "lon"=>121.54945}}], "overallOfficials"=>[{"name"=>"LEI ZHOU, M.D.", "role"=>"STUDY_CHAIR", "affiliation"=>"Ningbo Eye Hospital"}]}, "ipdSharingStatementModule"=>{"ipdSharing"=>"UNDECIDED"}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"Beijing Airdoc Technology Co., Ltd.", "class"=>"INDUSTRY"}, "collaborators"=>[{"name"=>"Ningbo Eye Hospital", "class"=>"OTHER"}], "responsibleParty"=>{"type"=>"PRINCIPAL_INVESTIGATOR", "investigatorTitle"=>"Myopia control officer", "investigatorFullName"=>"Qiu Kaikai", "investigatorAffiliation"=>"Ningbo Eye Hospital"}}}}
